About the 2nd Annual Neuroscience BioPartnering & Investment Forum

Following the success of the last year’s forum, we are pleased to announce the 2nd Annual Neuroscience BioPartnering & Investment Forum to take place on 27th of March at the New York Academy of Sciences. It will focus on key areas of neurodegenerative diseases and pain management with a mix of specialist panels and company presentations. The event is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma. We anticipate over 200 delegates and more than 20 presentations by listed and private biotechnology companies seeking licensing & investment opportunities. The forum’s networking is boosted by the use of our usual online one-to-one meeting system with dedicated meeting facilities. 
Plenary Sessions will include:
  • Neurotherapeutics-in-Development: A Progress Report
  • BioPartnering & DealMaking
  • Investor Roundtable
Therapeutic Panels will include:
  • Advances in Alzheimer’s Disease
  • Parkinson’s Disease & Other Movement Disorders
  • Rare & Orphan Diseases
  • Neuropsychiatry & Pain Management
Confirmed Keynote include:
  • “A Regenerative Approach to Neurodegenerative Diseases”
    by Dr. Daniel Alkon, President and CSO, Neurotrope Bioscience, Inc.​
Please note the recent passing away of Jeff Nye , Vice President, Neuroscience Innovation and Partnership Strategy, Johnson & Johnson, who was scheduled to join the opening panel. The organisers and speaker faculty send their condolences to his Family. 

http://www.legacy.com/obituaries/name/jeffrey-nye-obituary?pid=1000000184400339
Confirmed Speakers & Chairs include:
  • Alexander Breidenbach, Director, Global Business Development Neuroscience, F. Hoffmann-La Roche Ltd.
  • Allison Moore, Founder & CEO, Hereditary Neuropathy Foundation
  • Bob Linke, President and CEO, Embera NeuroTherapeutics, Inc.
  • Bruce Leuchter, Managing Director, PJT Partners
  • Carlos Buesa, CEO, Oryzon Genomics SA
  • Chaim Lebovits, CEO, BrainStorm Cell Therapeutics Ltd.
  • Daniel Alkon, Chief Scientific Officer, Neurotrope Bioscience, Inc.
  • Daniel O’Connell, Investment Manager, Arix Bioscience
  • Darryle Schoepp, Vice President, Neuroscience, Merck & Co., Inc.
  • David Bleakman, Vice President, Chief Scientific Officer - Neuroscience Discovery Research, New York City, Eli Lilly and Company
  • David Donabedian, Co-founder and CEO, Axial Biotherapeutics
  • Derek Small, President & CEO, Assembly Biosciences
  • Eugene Williams, Executive Chairman, ProMIS™ Neurosciences
  • Gerhard Koenig, President & Chief Executive Officer, Quartet Medicine
  • Ginger Johnson, CEO, Defined Health, a Cello Health business
  • Harry Tracy, President, NI Research, Inc.
  • Hendrik  Liebers, CFO , Probiodrug AG
  • Howard Fillit, Founding Executive Director and CSO, The Alzheimer's Drug Discovery Foundation
  • Isaac Veinbergs, Head of External Innovation, Neurosciences, Sanofi
  • Jak Knowles, Managing Director and VP Medical and Scientific Affairs, CureDuchenne Ventures
  • Jason Park, Principal, Flagship Ventures
  • Jon D.  Kaiser, CEO, K-PAX Pharmaceuticals
  • Jonathan Javitt, CEO, NeuroRx, Inc.
  • Kees Been, Founder, President and CEO, Lysosomal Therapeutics, Inc.
  • Kenneth J. Rhodes, CSO, Yumanity Therapeutics
  • Kiran Reddy, Venture Partner, Clarus Ventures, LLC
  • Kristen Kosofsky, Sr. Managing Director, Hercules Technology Growth Capital, Inc.
  • Leen Kawas, President & CEO, M3 Biotechnology, Inc.
  • Luca Benatti, CEO, Erydel SpA
  • Marc Martinell, CEO, Minoryx Therapeutics S.L.
  • Mark Day, Head, CNS Virtual Discovery, Purdue Pharma L.P.
  • Martin Heidecker, Managing Director, Boehringer Ingelheim Venture Fund USA, Inc.
  • Maxim Jacobs, Senior Healthcare Analyst, Edison Investment Research
  • Murali Gopalakrishnan, Senior Director & Head, Search & Evaluation Neuroscience, AbbVie, Inc.
  • Noelle Dubiansky, Partner, Goodwin Procter LLP
  • Ryan Westphal, Sr. Director, Neuroscience Search & Evaluation, Eli Lilly and Company
  • Shafique Virani, Head of Neuroscience, Ophthalmology and Rare Diseases Partnering, F. Hoffmann La Roche Ltd.
  • Steve Dickman, CEO, CBT Advisors
  • Todd Sherer, CEO, The Michael J. Fox Foundation
  • Vincent Miles, Partner, Abingworth LLP
  • Wayne Drevets, Vice President, Disease Area Leader in Mood Disorders, Neuroscience, Janssen Pharmaceutical Companies of Johnson & Johnson, Inc.
More Topics, Sessions and Keynotes to be announced...

Click HERE for information about the last year’s forum including speakers, presenters, attendees and other…
Sponsored by:
Supported by:
Pharma Licensing Groups ​
​Attending:

Financial
Advisory/Investors 
Attending in 2017:

A C Binder Corp.
Abingworth LLP
Aegis Capital Corp.
Alpha Bronze
Altius Strategy Consulting
Angel Investor
APS International
Athyrium Capital Management
CBT Advisors
Clarus Ventures, LLC
CureDuchenne Ventures
Deca Ventures
Deerfield Management
Defined Health
Edison Group
Flagship Ventures
Fraser Finance
H.C. Wainwright & Co, Inc.
Hercules Technology Growth Capital, Inc.
Katan Associates, Inc.
Landmark Family Office
Lexington Capital Management
Little Gem Life Sciences

​
Full List Here>>>